The economic cost of Alzheimer's disease: Family or public-health burden?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Dementia & Neuropsychologia |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642010000400262 |
Resumo: | Abstract Alzheimer's disease (AD) patients suffer progressive cognitive, behavioral and functional impairment which result in a heavy burden to patients, families, and the public-health system. AD entails both direct and indirect costs. Indirect costs (such as loss or reduction of income by the patient or family members) are the most important costs in early and community-dwelling AD patients. Direct costs (such as medical treatment or social services) increase when the disorder progresses, and the patient is institutionalized or a formal caregiver is required. Drug therapies represent an increase in direct cost but can reduce some other direct or indirect costs involved. Several studies have projected overall savings to society when using drug therapies and all relevant cost are considered, where results depend on specific patient and care setting characteristics. Dementia should be the focus of analysis when public health policies are being devised. South American countries should strengthen their policy and planning capabilities by gathering more local evidence about the burden of AD and how it can be shaped by treatment options. |
id |
ANCC-1_af458b78f9cf79fbd11671ddcae2ce96 |
---|---|
oai_identifier_str |
oai:scielo:S1980-57642010000400262 |
network_acronym_str |
ANCC-1 |
network_name_str |
Dementia & Neuropsychologia |
repository_id_str |
|
spelling |
The economic cost of Alzheimer's disease: Family or public-health burden?Alzheimer's diseaseeconomic costshealth economicsAbstract Alzheimer's disease (AD) patients suffer progressive cognitive, behavioral and functional impairment which result in a heavy burden to patients, families, and the public-health system. AD entails both direct and indirect costs. Indirect costs (such as loss or reduction of income by the patient or family members) are the most important costs in early and community-dwelling AD patients. Direct costs (such as medical treatment or social services) increase when the disorder progresses, and the patient is institutionalized or a formal caregiver is required. Drug therapies represent an increase in direct cost but can reduce some other direct or indirect costs involved. Several studies have projected overall savings to society when using drug therapies and all relevant cost are considered, where results depend on specific patient and care setting characteristics. Dementia should be the focus of analysis when public health policies are being devised. South American countries should strengthen their policy and planning capabilities by gathering more local evidence about the burden of AD and how it can be shaped by treatment options.Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento2010-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642010000400262Dementia & Neuropsychologia v.4 n.4 2010reponame:Dementia & Neuropsychologiainstname:Associação de Neurologia Cognitiva e do Comportamento (ANCC)instacron:ANCC10.1590/S1980-57642010DN40400003info:eu-repo/semantics/openAccessCastro,Diego M.Dillon,CarolMachnicki,GerardoAllegri,Ricardo F.eng2016-07-22T00:00:00Zoai:scielo:S1980-57642010000400262Revistahttp://www.demneuropsy.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||demneuropsy@uol.com.br1980-57641980-5764opendoar:2016-07-22T00:00Dementia & Neuropsychologia - Associação de Neurologia Cognitiva e do Comportamento (ANCC)false |
dc.title.none.fl_str_mv |
The economic cost of Alzheimer's disease: Family or public-health burden? |
title |
The economic cost of Alzheimer's disease: Family or public-health burden? |
spellingShingle |
The economic cost of Alzheimer's disease: Family or public-health burden? Castro,Diego M. Alzheimer's disease economic costs health economics |
title_short |
The economic cost of Alzheimer's disease: Family or public-health burden? |
title_full |
The economic cost of Alzheimer's disease: Family or public-health burden? |
title_fullStr |
The economic cost of Alzheimer's disease: Family or public-health burden? |
title_full_unstemmed |
The economic cost of Alzheimer's disease: Family or public-health burden? |
title_sort |
The economic cost of Alzheimer's disease: Family or public-health burden? |
author |
Castro,Diego M. |
author_facet |
Castro,Diego M. Dillon,Carol Machnicki,Gerardo Allegri,Ricardo F. |
author_role |
author |
author2 |
Dillon,Carol Machnicki,Gerardo Allegri,Ricardo F. |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Castro,Diego M. Dillon,Carol Machnicki,Gerardo Allegri,Ricardo F. |
dc.subject.por.fl_str_mv |
Alzheimer's disease economic costs health economics |
topic |
Alzheimer's disease economic costs health economics |
description |
Abstract Alzheimer's disease (AD) patients suffer progressive cognitive, behavioral and functional impairment which result in a heavy burden to patients, families, and the public-health system. AD entails both direct and indirect costs. Indirect costs (such as loss or reduction of income by the patient or family members) are the most important costs in early and community-dwelling AD patients. Direct costs (such as medical treatment or social services) increase when the disorder progresses, and the patient is institutionalized or a formal caregiver is required. Drug therapies represent an increase in direct cost but can reduce some other direct or indirect costs involved. Several studies have projected overall savings to society when using drug therapies and all relevant cost are considered, where results depend on specific patient and care setting characteristics. Dementia should be the focus of analysis when public health policies are being devised. South American countries should strengthen their policy and planning capabilities by gathering more local evidence about the burden of AD and how it can be shaped by treatment options. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642010000400262 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642010000400262 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1980-57642010DN40400003 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento |
publisher.none.fl_str_mv |
Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento |
dc.source.none.fl_str_mv |
Dementia & Neuropsychologia v.4 n.4 2010 reponame:Dementia & Neuropsychologia instname:Associação de Neurologia Cognitiva e do Comportamento (ANCC) instacron:ANCC |
instname_str |
Associação de Neurologia Cognitiva e do Comportamento (ANCC) |
instacron_str |
ANCC |
institution |
ANCC |
reponame_str |
Dementia & Neuropsychologia |
collection |
Dementia & Neuropsychologia |
repository.name.fl_str_mv |
Dementia & Neuropsychologia - Associação de Neurologia Cognitiva e do Comportamento (ANCC) |
repository.mail.fl_str_mv |
||demneuropsy@uol.com.br |
_version_ |
1754212930009694208 |